September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Preclinical insights into ocriplasmin safety and mechanism of action
Author Affiliations & Notes
  • Michaël PORCU
    Preclinical Research, ThromboGenics NV, LEUVEN, Flemish Brabant, Belgium
  • Isabelle Etienne
    Preclinical Research, ThromboGenics NV, LEUVEN, Flemish Brabant, Belgium
  • Aurélie Candi
    Preclinical Research, ThromboGenics NV, LEUVEN, Flemish Brabant, Belgium
  • Anne Verborg
    Preclinical Research, ThromboGenics NV, LEUVEN, Flemish Brabant, Belgium
  • Marianne Eelen
    Preclinical Research, ThromboGenics NV, LEUVEN, Flemish Brabant, Belgium
  • Bart Jonckx
    Preclinical Research, ThromboGenics NV, LEUVEN, Flemish Brabant, Belgium
  • Jean H.M. Feyen
    Preclinical Research, ThromboGenics NV, LEUVEN, Flemish Brabant, Belgium
  • Footnotes
    Commercial Relationships   Michaël PORCU, ThromboGenics NV (E); Isabelle Etienne, ThromboGenics NV (E); Aurélie Candi, ThromboGenics NV (E); Anne Verborg, ThromboGenics NV (E); Marianne Eelen, ThromboGenics NV (E); Bart Jonckx, ThromboGenics NV (E); Jean Feyen, ThromboGenics NV (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4044. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Michaël PORCU, Isabelle Etienne, Aurélie Candi, Anne Verborg, Marianne Eelen, Bart Jonckx, Jean H.M. Feyen; Preclinical insights into ocriplasmin safety and mechanism of action. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4044.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to gain insight into the safety and mechanism of action of ocriplasmin, a protease used for treatment of vitreomacular traction. To achieve this, we evaluated retina and vitreous tissues from a porcine model of ocriplasmin-induced Posterior Vitreous Detachment (PVD) as well as cell-based models.

Methods : Porcine eyes were injected intravitreally with ocriplasmin (96μg per eye, equivalent to 125μg in human) or vehicle. At several time points (up to 6 weeks) post injection, animals were sacrificed and vitreoretinal tissues were studied: retinal morphology, distribution of extracellular matrix proteins as well as number of microglial cells were histologically examined. The presence of an inflammatory response was assessed by multiplex profiling of 14 inflammatory markers in the vitreous. The effect of ocriplasmin on blood-retinal-barrier permeability was assessed using an in vitro electrical resistance (TEER) assay.

Results : Retinal morphology was not affected by vehicle or ocriplasmin at any of the investigated time points. Extracellular matrix components clearly delineated the PVD structures at the internal limiting membrane and no significant distribution changes were observed in the retina. No evidence for a major acute inflammatory response was found. Although histology indicated a minor increase of the macrophage-specific marker Iba1 in ocriplasmin treated eyes, cytokine profiling indicated no significant difference between vehicle and ocriplasmin treated eyes. A minor and transient inflammatory response related to injection in general was observed. We observed that only high doses of ocriplasmin could modulate permeability of in vitro retinal barrier models, all changes being cell specific and fully reversible after 48 hours.

Conclusions : A number of the transient observations on OCT (lucencies, inclusions) that have been observed in patients treated with ocriplasmin can be mimicked in a porcine model of PVD. Closer examination of the involved tissues did not indicate an underlying acute inflammatory response, neither did we observe signs of toxicity or extracellular matrix rearrangement specific to ocriplasmin. In vitro observations indicate that retinal barrier permeability can only be affected by high local doses of active ocriplasmin, and even then the effects are rapidly reversible.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×